I think that's a bit cynical of the current round of bio-based funding. It's not wrong, but it's also not the whole picture. It's only just started, but there

I think that's a bit cynical of the current round of bio-based funding. It's not wrong, but it's also not the whole picture. It's only just started, but there is now a light at the end of the genetic/gene-therapy tunnel. With the approval of the first CAR last year (and it's success at curing children of leukemia), there's now a very real environment to produce valuable inventive biological products that are not just chemicals or antibodies. Kite and Juno sales for ~$10B each earlier this year has done quite a bit for the field. Vapor always follows the good money, but it's not just that the money is cheap.